Charles Schwab Investment Management Inc. Sells 57,954 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Key Points

• Charles Schwab Investment Management Inc. decreased its holdings in BioCryst Pharmaceuticals by 2.9%, owning approximately 1.92 million shares of the company, valued at around $14.42 million as of the last reporting period.
• Analysts have mostly positive views on BioCryst Pharmaceuticals, with nine research analysts rating it a "Buy" and an average price target of $16.70.
• BioCryst Pharmaceuticals reported $0.15 earnings per share for the most recent quarter, significantly surpassing the consensus estimate of $0.03, and showing a 49.5% increase in revenue year-over-year.

Charles Schwab Investment Management Inc. lowered its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 2.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,922,038 shares of the biotechnology company's stock after selling 57,954 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.92% of BioCryst Pharmaceuticals worth $14,415,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new position in shares of BioCryst Pharmaceuticals in the fourth quarter worth $33,000. GAMMA Investing LLC increased its holdings in shares of BioCryst Pharmaceuticals by 1,161.8% in the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock worth $44,000 after purchasing an additional 5,449 shares during the period. New Age Alpha Advisors LLC bought a new position in shares of BioCryst Pharmaceuticals in the first quarter worth $62,000. Allspring Global Investments Holdings LLC bought a new position in shares of BioCryst Pharmaceuticals in the first quarter worth $79,000. Finally, Raymond James Financial Inc. bought a new position in shares of BioCryst Pharmaceuticals in the fourth quarter worth $80,000. Institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Stock Down 0.9%

Shares of BioCryst Pharmaceuticals stock traded down $0.08 during trading on Thursday, reaching $8.45. 1,060,603 shares of the stock were exchanged, compared to its average volume of 3,741,340. The stock's fifty day moving average is $8.73 and its 200 day moving average is $8.79. The firm has a market cap of $1.77 billion, a price-to-earnings ratio of -46.91, a price-to-earnings-growth ratio of 1.95 and a beta of 1.10. BioCryst Pharmaceuticals, Inc. has a 1 year low of $6.01 and a 1 year high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.03 by $0.12. The company had revenue of $163.35 million during the quarter, compared to analysts' expectations of $149.59 million. During the same quarter last year, the business earned ($0.06) earnings per share. The business's quarterly revenue was up 49.5% on a year-over-year basis. Equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Insider Buying and Selling

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of the firm's stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total value of $595,700.00. Following the completion of the sale, the director directly owned 65,352 shares in the company, valued at $556,145.52. This trade represents a 51.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 5.10% of the stock is owned by company insiders.

Analyst Ratings Changes

BCRX has been the topic of a number of research analyst reports. Needham & Company LLC reissued a "buy" rating and issued a $17.00 target price on shares of BioCryst Pharmaceuticals in a research note on Monday, August 4th. Bank of America increased their target price on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a "buy" rating in a research note on Tuesday, July 1st. Wedbush increased their target price on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a research note on Monday, June 30th. JPMorgan Chase & Co. increased their target price on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a research note on Tuesday, May 6th. Finally, HC Wainwright reissued a "buy" rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $16.70.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.